Catheter Ablation for Atrial Fibrillation and Ventricular Tachycardia: A Chinese Registry

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, prospective, non-randomized registry designed to collect long-term data on the safety and effectiveness of catheter ablation for AF and VT in Chinese patients. It is divided into two cohorts: AF and VT, with the AF cohort examining different ablation workflows and AF recurrence in relation to long-term outcomes, while the VT cohort evaluates the impact of novel ablation technologies. Data will inform future diagnostic and management strategies for complex arrhythmias and help refine patient selection and follow-up. The study uses 3D mapping systems for AF ablation and includes adults undergoing first-time AF ablation. No randomization or active treatment assignment is involved beyond standard-of-care ablation procedures.

Why it matters

Who can join: the full rules

1. Atrial Fibrillation (AF) Cohort:

   * Inclusion Criteria (Patients must meet ALL of the following criteria):

     1. Age ≥ 18 years.
     2. Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).
     3. Scheduled to undergo first-time catheter ablation for AF.
     4. Procedure to be performed using a 3D mapping system.
     5. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.
   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):

     1. Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).
     2. AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).
     3. Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment/procedure.
     4. Severe active infection (e.g., septic shock, sepsis).
     5. Contraindications to anticoagulation therapy.
     6. Current participation in another interventional clinical trial that may confound the results of this study.
     7. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.
2. Ventricular Tachycardia (VT) Cohort

   * Inclusion Criteria (Patients must meet ALL of the following criteria):

     1. Age ≥ 18 years.
     2. Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including:
     3. Ischemic heart disease (e.g., prior MI, coronary artery disease).
     4. Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)).
     5. Scheduled to undergo first-time catheter ablation for VT.
     6. Procedure to be performed using a 3D mapping system.
     7. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.
   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):

     1. VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance).
     2. Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease).
     3. Cardiac surgery within 60 days prior to the planned ablation procedure.
     4. Severe coagulopathy (e.g., platelet count \< 50 x 10⁹/L, disseminated intravascular coagulation (DIC)).
     5. Severe heart failure with left ventricular ejection fraction (LVEF) \< 20%.
     6. Severe active infection (e.g., septic shock, sepsis).
     7. Current participation in another interventional clinical trial that may confound the results of this study.
     8. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.

Where it's running

• No. 2 Anzhen Rd, Chaoyang District, 100029
  Beijing, Beijing Municipality, China Recruiting
• Beijing Anzhen Hospital, Capital Medical University
  Beijing, China Not yet recruiting

Study contacts

• Principal investigator: Deyong Long — Beijing Anzhen Hospital
• Study coordinator: Deyong Long, MD
• Email: dragon2008@vip.sina.com
• Phone: +86 (010) 84005361

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tracking outcomes after heart rhythm procedures in Düsseldorf.

  This registry collects information to see how safe and effective routine electrophysiology procedures (like catheter ablation and cardioversion) are for people treated for AF, atrial flutter, supraventricular tachycardias, or VT at University Hospital Düsseldorf.

  Recruiting Heinrich-Heine University, Duesseldorf · Düsseldorf · NCT07196176

• Pulsed Field vs Cryoballoon for Pulmonary Vein Isolation in Atrial Fibrillation

  This trial tests whether pulsed field ablation can shorten the procedure for first-time PVI in AF patients compared with cryoballoon ablation, while keeping safety and effectiveness similar.

  Recruiting St. Josefs-Hospital Wiesbaden GmbH · Wiesbaden · NCT07910370

• Pulsed Field Ablation vs Cryoablation for Atrial Fibrillation Under Deep Sedation

  This trial tests whether pulsed field ablation (PFA) done under deep sedation works as well as cryoballoon ablation for treating atrial fibrillation, aiming to avoid general anesthesia.

  Recruiting East Sussex Healthcare NHS Trust · Eastbourne · NCT07900685

• Bachmann’s Bundle Pacing vs Right Atrial Appendage Pacing for AF

  This study tests two common atrial pacing methods to see which one is safer over 12 months for people getting a new pacemaker, ICD, or CRT device.

  Recruiting Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07874763

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes

  This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.

  Recruiting at 5 sites Insel Gruppe AG, University Hospital Bern · Zabrze and 4 other locations · NCT07852221

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.